Ascletis, Inc. Gains China Market Rights From Janssen Research & Development to a Clinical Stage HIV Protease Inhibitor
4/30/2013 10:55:32 AM
More...
|
Week in Review: Ascletis, Inc. Collaborates With Roche (RHHBY) on HCV Treatment
4/22/2013 9:24:09 AM
More...
|
Roche (RHHBY), Ascletis, Inc. to Collaborate on Hepatitis C Drugs for China
4/15/2013 8:46:10 AM
More...
|
ChinaBio(R) LLC Week in Review: Ascletis, Inc. In-Licenses China Rights to RNAi Cancer Drug
7/16/2012 9:04:34 AM
More...
|
US-China Pharmaceutical Venture Ascletis, Inc. Receives Record-Level Research and Development Grant from Hangzhou
1/4/2012 8:40:12 AM
More...
|
Ascletis, Inc. Named for Financing Deal of the Year
11/30/2011 12:32:13 PM
More...
|
Ascletis, Inc. Adds Support to $100 Million in Startup Capital
7/21/2011 2:30:52 PM
More...
|
Ascletis, Inc. Announces New Support from Hangzhou, China and The Hamner Institutes for Health Sciences in Research Triangle Park, NC
7/20/2011 8:26:32 AM
More...
|
Ascletis, Inc. Names Allan Baxter, PhD, Former GlaxoSmithKline (GSK) Global Head of Medicines Development, as Chief Strategy Officer
7/11/2011 9:43:15 AM
More...
|
US-China Based Ascletis, Inc. Raises $100 Million from Private Chinese Investors for Specialty Therapeutics Venture
4/6/2011 6:58:06 AM
More...
|